When an mGluR1 antagonist or Riluzole, a glutamate release inhibitor, was used to treat melanoma cells expressing mGluR1, cell proliferation, tumor growth, and extracellular glutamate levels were all decreased significantly, with tumor growth decreasing by up to 50%8,9,11. Here, GRM1 is linked to melanoma.